07:00 , Jun 9, 2011 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

This week in techniques Approach Summary Licensing status Publication and contact information Disease models Mouse models of low-density lipoprotein receptor-related protein 5 (LRP5)-driven regulation of bone mass A...
08:00 , Nov 5, 2009 |  BC Innovations  |  Targets & Mechanisms

Norrin vs. VEGF

Two papers in Celldescribe a new signaling pathway that acts upstream of VEGF to control vascular development in the embryonic retina. The pathway is also present in adults, but the question is whether it's actually...
08:00 , Jan 8, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Musculoskeletal disease

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Musculoskeletal disease ...
08:00 , Mar 5, 2007 |  BioCentury  |  Product Development

Beyond 'me better'

Osteoporosis represents one of the paradoxes of modern drug development, where a huge market and the success of current treatments provides few incentives for novel approaches, even though the relatively small number of therapeutic alternatives...
08:00 , Mar 5, 2007 |  BioCentury  |  Product Development

Bone remodeling targets

Bone remodeling targets Bone is continuously broken down by osteoclasts and formed by osteoblasts. Studying this cycle has revealed a number of targets for use as potential treatments for bone diseases like osteoporosis. One of the...
08:00 , Nov 13, 2006 |  BC Week In Review  |  Company News

Raptor Pharmaceuticals Corp., Washington University deal

RPTP licensed exclusive worldwide rights to the university's proteins and peptides derived from the mesoderm development (Mesd) gene sequence for therapeutic use in cancer and bone diseases. The Mesd gene encodes a chaperone protein specific...
07:00 , May 9, 2005 |  BioCentury  |  Strategy

Acquiring markets

When French drug discovery play ProSkelia SA and U.K. specialty pharma Strakan Group Ltd. merged last year to form ProStrakan Group Ltd., one of the newco's first goals was to extend its reach in European...
07:00 , Jun 14, 2004 |  BioCentury  |  Strategy

Strakan-ProSkelia pipeline

Strakan-ProSkelia pipeline Product Indication Status Notes Strakan Zindaclin Acne Mkt Acquired from Access; outlicensed to Fujisawa for continental Western Europe and to Pliva for Eastern Europe, Israel and parts of Asia Isotard XL Angina...
08:00 , Jan 6, 2003 |  BC Week In Review  |  Company News

Genome Therapeutics, Wyeth deal

The companies extended through December 2003 their 1999 research agreement to develop therapeutics for osteoporosis based on the LRP5 gene. GENE said that to date it has received $9 million of the $118 million...
08:00 , Dec 24, 2001 |  BC Week In Review  |  Company News

Genome Therapeutics other research news

Scientists reported in the American Journal of Human Genetics that linkage and sequence analysis of chromosome 11 in >1,000 people identified a mutation in the LRP5 gene that correlates with the high bone mass phenotype....